Please ensure Javascript is enabled for purposes of website accessibility

OrganiGram Releases Cannabis 2.0 Products To Medical Users

By Bradley Freeman – May 28, 2020 at 1:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Vapes and chocolate edibles are among the new cannabis products the company is rolling out to medical marijuana consumers.

Like many Canadian cannabis companies, OrganiGram (OGI -0.81%) (OGI -3.79%) has had a tough year, losing 75% of its value over 12 months and having to dip into the markets to raise cash.

Growing pains associated with Canadian cannabis legalization plagued OrganiGram's once-promising roll out of regulated cannabis products. Optimistic executives did not help manage investors' expectations.

Weed cookies

Image Source: Getty Images

Help is coming

Fortunately for the company, a positive catalyst is now easing some of the pain. In January, the Canadian government began its cannabis 2.0 program in which derivative products made from the marijuana plant can be legally sold in the form of an oil to be cooked into an edible product, used as a trans-dermal product like lotion, or used with a vaporizer.

Cannabis derivatives carry a higher margin than dried cannabis; producers make more money by selling a processed candy than they do the plant itself. 

Product release

This week, OrganiGram finally released its medical line of cannabis 2.0 products, including "Edison vape pens powered by Feather; Edison-branded pods specifically for PAX Era vaporizers; and Edison Bytes chocolates in dark and milk chocolate, in both one and two pack formats," according to its press release.

This launch comes months after other companies launched theirs. For instance, Aurora Cannabis (ACB -2.40%) released its competing product lines in January. 

Earlier this year, OrganiGram tested its preliminary shipments of derivative products to see how they were received among users. The next few months were dedicated to perfecting recipes and preparing for market launch.

Now OrganiGram can begin to realize the incremental sales associated with derivative revenue as its competition has been doing so far this year. While the cannabis producer was late to the party, this news is a welcome development for investors.

Bradley Freeman owns shares of Aurora Cannabis Inc. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool recommends OrganiGram Holdings. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OrganiGram Holdings Stock Quote
OrganiGram Holdings
$0.87 (-3.79%) $0.03
OrganiGram Holdings Stock Quote
OrganiGram Holdings
$1.22 (-0.81%) $0.01
Aurora Cannabis Stock Quote
Aurora Cannabis
$1.22 (-2.40%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.